Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

NCT01746836 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Ponatinib Hydrochloride
OTHER: Quality-of-Life Assessment

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]